MedWatch

Demant's 2022 growth prognosis to take center stage in full-year report after accidental release

Because Demant has already accidentally released the full-year financial figures for organic growth and operating profits on its website, the focus will be elsewhere tomorrow, when the finished report is released, says Sydbank, which will look to the growth guidance for the new year instead.

Photo: Demant / PR

More so than usual, attention will be fixed on Demant’s 2022 guidance when the hearing aid firm presents its full-year financial report on Tuesday.

Over the past half year, the company has given several indications of what to expect in that time frame, which leaves the question of how 2022 started off for Demant, as well as what comes next.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs